Navigation Links
Vasomedical to Report Third Quarter 2013 Results on November 14, 2013
Date:11/5/2013

WESTBURY, N.Y., Nov. 5, 2013 /PRNewswire/ -- Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended September 30, 2013 on Thursday, November 14, 2013.

The Company will host a conference call on Thursday, November 14th at 1:00 p.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical, and Michael Beecher, Chief Financial Officer of Vasomedical. To dial into the conference call, please dial 1-866-393-1344 from the U.S. or 1-631-291-4669, internationally. All dial-in participants must use the following code to access the call: 94523097. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical's website, www.vasomedical.com, and www.kcsa.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.vasomedical.com or www.kcsa.com. To access the dial-in replay of the call, which will be available until December 16, 2013, please dial 1-855-859-2056 or 1-404-537-3406. All dial-in participants must use the following code to access the call: 94523097.

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sal
'/>"/>

SOURCE Vasomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vasomedical Announces Financial Results for the Second Quarter of 2013
2. Vasomedical to Report Second Quarter 2013 Results on August 13, 2013
3. Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
4. Vasomedical Announces Financial Results for the First Quarter of 2013
5. Vasomedical to Report First Quarter 2013 Results on May 15, 2013
6. Randy Hill Appointed to Vasomedical Board of Directors
7. Vasomedical Announces Share Repurchase Program of up to $1.5 Million in Common Stock
8. Vasomedical Announces Financial Results for the Fourth Quarter and Year Ended 2012
9. Vasomedical to Report Fourth Quarter and Year End 2012 Results on April 1, 2013
10. Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Vasomedical, Inc. to Present Live Webcast at RetailInvestorConferences.com on February 7th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Mr. Amar Singh , Chief Business Officer and Executive ... natural causes on July 30. "Sorrento is deeply ... and colleague. Our immediate thoughts go to Amar,s family and ... Chief Executive Officer. Mr. Singh joined Sorrento ...
(Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14
... Invuity, a leading developer of state-of-the-art illuminated surgical ... at the American College of Surgeons, 97th Annual ... specifically for breast mastectomies, lumpectomies, sentinel node biopsies ... proprietary Eigr ™ (pronounced eye-gr) illumination technology ...
... Generex Biotechnology Corporation (OTCBB: GNBT) ( www.generex.com ) announced ... conference call for late November.  The purpose of the ... (i) the status of the Company,s efforts in respect ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), (ii) financing ...
Cached Medicine Technology:Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures 2Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures 3Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3
(Date:8/2/2014)... According to the Girl Gets Ring System review ... for women. The book consists of dating tips and tricks ... book also teaches women how to deal with relationship ... its review that this book is divided into 10 chapters ... Story? ,     Chapter 2 – How A Traffic Light ...
(Date:8/2/2014)... On July 21, 2014, the Johns Hopkins Health ... settle the class action lawsuit filed October 24, ... 24-C-13-001041 MM, on behalf of thousands of women who allegedly ... According to The Baltimore Sun , the $190 ... a physician accused of sexual misconduct. , An investigation prompted ...
(Date:8/1/2014)... The successful development of C60F projects is of ... Automobile Co.,LTD. As early as the very beginning of ... excellent team to develop a comprehensive plan to carry ... The company’s vice president Liming Yang and some of ... the specific arrangement and the supervision of the project ...
(Date:8/1/2014)... of Medicine in St. Louis helps explain why brain ... more harmful than similar tumors in females. For example, ... twice as often in males, who suffer greater cognitive ... , The researchers found that retinoblastoma protein (RB), a ... active in male brain cells than in female brain ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 2Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 3Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2
... House ceremony next month, Thomas L. Kash, PhD, assistant professor ... for Alcohol Studies at the University of North Carolina at ... Career Award for Scientists and Engineers (PECASE). , This is ... science and engineering professionals in the early stages of their ...
... in the October 2011 issue of The FASEB ... "healthy" ingredient in red wine, stops breast cancer cells ... This discovery, made by a team of American and ... is able to counteract the malignant progression since it ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Sept. 28 ... advanced Alzheimer,s or other form of severe dementia will be shuttled ... months of life, a new U.S. study shows. The ... Depending on where a patient lives, as many as ...
... the British Journal of Sports Medicine * highlights the injury ... chance of a school player suffering an injury during a single ... research, could be as high as 90 per cent. The ... City University say there is an urgent need to inform children, ...
... with dementia can still make decisions in their everyday lives ... as their condition advances. This is one of the preliminary ... and Social Research Council (ESRC) into how married couples living ... study is investigating how couples make decisions over issues such ...
... dose of the hallucinogen psilocybin, the active ingredient in ... measureable personality change lasting at least a year in ... new study, according to the Johns Hopkins researchers who ... part of the personality known as openness, which includes ...
Cached Medicine News:Health News:UNC researcher to receive highest US honor for early career science professionals 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 3Health News:Academic issues warning on schoolboy rugby 2Health News:Living with dementia and making decisions 2Health News:Single dose of hallucinogen may create lasting personality change 2Health News:Single dose of hallucinogen may create lasting personality change 3
... Oncotype DX™ is a diagnostic assay that ... in women with newly diagnosed, early stage ... disease recurrence, Oncotype DX also assesses the ... assay performed using formalin-fixed, paraffin-embedded tumor ...
... HER2 FISH pharmDx Kit is a direct ... to quantitatively determine HER2 gene amplification in ... amplification is determined from the ratio between ... of the HER2 gene probe (red signals) ...
... age of 3 can choose either the PARI ... design principle applies to both:, ,Maximize aerosol ... output when the patient exhales using two one-way ... leave the nebulizer. The result is a high ...
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
Medicine Products: